Abstract
Predictive values of miR-129 and miR-139 for efficacy on patients with prostate cancer (PC) after chemotherapy and prognostic correlation were explored. Eighty-four patients with PC undergoing chemotherapy in The Third Affiliated Hospital of Qiqihar Medical University from January 2016 to January 2017 were enrolled as the observation group treated with DP regimen, and further 100 healthy individuals undergoing physical examination were enrolled as the control group. RT-qPCR was used to detect expression of serum miR-129 and miR-139. According to the clinical efficacy after treatment, patients with complete remission (CR) and partial remission (PR) were considered as a good curative effect group, whereas those with stable disease (SD) and progressive disease (PD) were considered as a poor curative effect group. In the observation group, miR-129 and miR-139 expression after treatment was significantly lower and higher, respectively, than that before treatment (P<0.05). After treatment, there were 15 patients with CR, 30 with PR, 26 with SD, and 13 with PD in the observation group. Before treatment, compared with the poor curative effect group, patients in the good curative effect group had significantly higher miR-129 expression but significantly lower miR-139 expression (P<0.05). The overall survival rate (OSR) of patients was 64.29%. The survival of patients in the miR-129 high expression group was significantly better than that in the miR-129 low expression group (P=0.001), whereas the survival in the miR-139 low expression group was significantly better than that in the miR-139 high expression group (P=0.012). According to multivariate Cox regression analysis, Gleason score, prostate specific antigen (PSA), bone metastasis, TNM staging, miR-129, and miR-139 were independent prognostic factors affecting patients. In conclusion, miR-129 and miR-139 are expected to be potential indicators for the diagnosis, prognosis, and efficacy prediction of PC.